TIMOTHY PEBBLES: Open Payments
NPI 1730512823 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,159 in 47 payments from 12 companies in 2025. Trend: 2023 $1,057 · 2024 $1,184 · 2025 $1,159
Food & beverage: $1,095Education: $64
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $419 |
| Regeneron Healthcare Solutions, Inc. | 7 | $198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| GlaxoSmithKline, LLC. | 4 | $90 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $63 |
| Lilly USA, LLC | 3 | $63 |
| Incyte Corporation | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $52 |
| GENZYME CORPORATION | 1 | $40 |
| Genentech USA, Inc. | 2 | $35 |
Products named: DUPIXENT, TEZSPIRE, FASENRA, NUCALA, AIRSUPRA, NEFFY, EBGLYSS, OPZELURA.
Industry payments across MI — which companies pay providers there.
